No­var­tis nabs FDA ap­proval for hyped Eylea ri­val

As Re­gen­eron’s Eylea stares down po­ten­tial slow-death-by-gener­ics, No­var­tis has nabbed a wide­ly ex­pect­ed FDA ap­proval for its own wet mac­u­lar de­gen­er­a­tion in­jec­tion, Beovu (brolu­cizum­ab).

No­var­tis has been eye­ing Re­gen­eron patent ex­pi­ra­tion with the leer­ing in­ten­si­ty of a prowl­ing tiger. Be­fore be­com­ing CEO in 2017, Vas Narasimhan iden­ti­fied brolu­cizum­ab as one of four big late-stage drugs to watch, and in 2018 he named it one of the “core 5” in his list of 25 block­busters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER